Re-appointment of Ms. Esha Padmanabhan Achan (DIN:10350369), as a Non- Executive Independent Director of the company.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Rossari Biotech's Board approved the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of 3 years, from October 21, 2026 to October 20, 2029, subject to shareholder approval. Ms. Esha is a finance professional with 33 years of experience, having held senior roles at Glenmark Pharmaceuticals and Bajaj. The Board also approved a grant of 830,050 stock options under the Rossari Employee Stock Option Plan 2019, with an exercise price of Rs. 537 per option. The options vest over 4 years (20% each year for 3 years, then 40% in the 4th year) and can be exercised within 5 years of vesting.
The re-appointment maintains board continuity and good governance practice. The ESOP grant aligns employee interests with shareholders but will result in dilution of approximately 830,050 equity shares upon full exercise.